NO20030899L - Anvendelse av salmeterol og fluticasonpropionat kombinasjon - Google Patents

Anvendelse av salmeterol og fluticasonpropionat kombinasjon

Info

Publication number
NO20030899L
NO20030899L NO20030899A NO20030899A NO20030899L NO 20030899 L NO20030899 L NO 20030899L NO 20030899 A NO20030899 A NO 20030899A NO 20030899 A NO20030899 A NO 20030899A NO 20030899 L NO20030899 L NO 20030899L
Authority
NO
Norway
Prior art keywords
salmeterol
fluticasone propionate
propionate combination
combination
fluticasone
Prior art date
Application number
NO20030899A
Other languages
English (en)
Other versions
NO20030899D0 (no
Inventor
Donald Herbert Hortsman
Claire Julia Maden
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20030899D0 publication Critical patent/NO20030899D0/no
Publication of NO20030899L publication Critical patent/NO20030899L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
NO20030899A 2000-08-31 2003-02-26 Anvendelse av salmeterol og fluticasonpropionat kombinasjon NO20030899L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22938100P 2000-08-31 2000-08-31
PCT/GB2001/003928 WO2002017894A2 (en) 2000-08-31 2001-08-31 Pharmaceutical formulation of salmeterol and fluticasone propionate

Publications (2)

Publication Number Publication Date
NO20030899D0 NO20030899D0 (no) 2003-02-26
NO20030899L true NO20030899L (no) 2003-04-28

Family

ID=22860986

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030899A NO20030899L (no) 2000-08-31 2003-02-26 Anvendelse av salmeterol og fluticasonpropionat kombinasjon

Country Status (24)

Country Link
US (1) US20040009963A1 (no)
EP (1) EP1313484A2 (no)
JP (1) JP2004507494A (no)
KR (1) KR20030031997A (no)
CN (1) CN1449288A (no)
AP (1) AP2003002753A0 (no)
AR (1) AR030516A1 (no)
AU (1) AU2001284236A1 (no)
BG (1) BG107596A (no)
BR (1) BR0113555A (no)
CA (1) CA2420532A1 (no)
EA (1) EA200300152A1 (no)
EC (1) ECSP034487A (no)
HU (1) HUP0303755A2 (no)
IL (1) IL154403A0 (no)
MA (1) MA25834A1 (no)
MX (1) MXPA03001752A (no)
NO (1) NO20030899L (no)
OA (1) OA12370A (no)
PE (1) PE20020387A1 (no)
PL (1) PL365582A1 (no)
SK (1) SK2302003A3 (no)
WO (1) WO2002017894A2 (no)
ZA (1) ZA200301475B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0106031D0 (en) * 2001-03-12 2001-05-02 Glaxo Group Ltd Use
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US20070071689A1 (en) * 2003-08-06 2007-03-29 Galephar M/F Advantageous combination for inhalation of nacystelyn and bronchodilators
TR200907913A2 (tr) * 2009-10-20 2011-05-23 Bi̇lgi̇ç Mahmut İnhalason yolu ile alınmak üzere kuru toz formunda farmasötik bileşim
TR201000681A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut İnhalasyon yoluyla alınan kuru toz formülasyonları.
TR200909791A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Salmeterol ve flutikazon içeren farmasötik bileşim@
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
WO2014007781A2 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
EP2991625A1 (en) * 2013-04-29 2016-03-09 Sanofi SA Inhalable pharmaceutical compositions and the inhaler devices containing them
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
GB9808802D0 (en) * 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
GB9924992D0 (en) * 1999-10-21 1999-12-22 Glaxo Group Ltd Pharmaceutical aerosol formulations
AU2206801A (en) * 1999-12-24 2001-07-09 Alan Leslie Cripps Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate

Also Published As

Publication number Publication date
HUP0303755A2 (hu) 2004-04-28
CN1449288A (zh) 2003-10-15
MA25834A1 (fr) 2003-07-01
MXPA03001752A (es) 2003-06-04
WO2002017894A3 (en) 2002-08-08
WO2002017894A2 (en) 2002-03-07
PE20020387A1 (es) 2002-06-24
AU2001284236A1 (en) 2002-03-13
US20040009963A1 (en) 2004-01-15
BG107596A (bg) 2004-01-30
PL365582A1 (en) 2005-01-10
NO20030899D0 (no) 2003-02-26
BR0113555A (pt) 2003-07-22
AP2003002753A0 (en) 2003-06-30
KR20030031997A (ko) 2003-04-23
ECSP034487A (es) 2003-03-31
SK2302003A3 (en) 2003-08-05
AR030516A1 (es) 2003-08-20
EA200300152A1 (ru) 2003-08-28
ZA200301475B (en) 2004-05-24
EP1313484A2 (en) 2003-05-28
OA12370A (en) 2004-03-19
JP2004507494A (ja) 2004-03-11
CA2420532A1 (en) 2002-03-07
IL154403A0 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
NO2019003I1 (no) Kombinasjon av formoterolfumarat dihydrat og beklometason-dipropionat
DK1152753T3 (da) Kombinationer af formoterol og fluticasonpropionat til astma
DE60141247D1 (de) Bandkassette und bandeinheit
DK1329456T3 (da) Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
NO20030725D0 (no) Terapeutisk kombinasjon av CETP-inhibitor og atorvastatin
DE50112013D1 (de) Deodorantien und antiperspirantien
NO20035158D0 (no) Oksidativ halogenering av C1-hydrokarboner til halogenerte C1- hydrokarbonerog integrerte fremgangsmåter relatert til dette
DE60026022D1 (de) Fluor enthaltende allylether und höhere homologe
NO20030397L (no) Amyloid målsökende billeddannende midler og anvendelser av samme
NO20023342D0 (no) Fremgangsmåte for fjernelse av NOX og N2O
NO20015542L (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
NO20005440L (no) Pakkebaserte personlig utstyrsarrangementer og - fremgangsmåter
NO20030899D0 (no) Anvendelse av salmeterol og fluticasonpropionat kombinasjon
NO20011026D0 (no) Matvare og fremgangsmÕte for fremstilling derav
DE60120291D1 (de) Endoskop und Endoskopkapsel
NO20015772L (no) Forbindelser og fremgangsmåter for behandling av post- traumatisk stress-syndrom
DE60107990D1 (de) Foliebehandlungsvorrichtung und Umwickelvorrichtung
DE60144529D1 (de) Bandkassette und bandeinheit
NO20032821D0 (no) Sea-trosy og beslektede fremgangsmåter
NO20013534D0 (no) Blodströmsforbedringsmidler og trombose-hemmere eller - remedier
NO20026148L (no) Medisiner for forhindring og behandling av neurodegenerative sykdommer
NO20026065D0 (no) Prosesser for måling av dinofysistoksin og av yessotoksin
NO20014454D0 (no) Konstruksjon og anvendelse av samme
NO995314D0 (no) For og anvendelse av slikt for
SI1152753T1 (en) Combinations of formoterol and fluticasone propionate for asthma

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application